26 August 2015Americas

US and Brazil clear path for Pfizer’s Hospira buyout

Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Hospira patent dispute revived

14 September 2015 A US appeals court has revived a dispute in which a lower court previously ruled that there should not be a trial to determine whether pharmaceutical company Hospira infringed three patents.

Americas

Pfizer’s Hospira buyout approved in Australia and Canada

18 August 2015 Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.

Americas

European Commission approves Pfizer’s buyout of Hospira

6 August 2015 The European Commission has approved US pharmaceutical company Pfizer’s $17 billion acquisition of Hospira, a move that will see Pfizer acquire the drugs company’s biosimilar portfolio.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

US and Brazil clear path for Pfizer’s Hospira buyout

More on this story

Editor's picks

Editor's picks

More features